Regulation of cardiac expression of the diabetic marker microRNA miR-29

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Arnold, Nicholas ^a,b   Koppula, Purushotham Reddy ^a,b   Gul, Rukhsana ^a,b,c   Luck, Christian ^a,b   Pulakat, Lakshmi ^a,b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MICRORNA 29; MICRORNA 29A; MICRORNA 29B; MICRORNA 29C; PROTEIN MCL 1; RAPAMYCIN; S6 KINASE; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; MCL1 PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MICRORNA; MIRN29 MICRORNA, HUMAN; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HEART DISEASE; HEART INJURY; HEART MUSCLE CELL; HEART WEIGHT; IN VITRO STUDY; INSULIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; RAT; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; CARDIAC MUSCLE CELL; DRUG EFFECTS; GENETICS; GLUCOSE BLOOD LEVEL; HEART DISEASES; HUMAN; METABOLISM; PANCREAS ISLET BETA CELL; PATHOLOGY;

ANIMALS; BLOOD GLUCOSE; DIABETES COMPLICATIONS; GENE EXPRESSION REGULATION; HEART DISEASES; HUMANS; INSULIN; INSULIN-SECRETING CELLS; MICE; MICRORNAS; MULTIPROTEIN COMPLEXES; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; MYOCYTES, CARDIAC; RATS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84905014949     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103284     Document Type: Article

References (45)

1. Masoudi FA, Inzucchi SE (2007) Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol 99: 113B-132B.
2. Poornima IG, Parikh P, Shannon RP (2006) Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 98: 596-605.
3. Raymond T, Raymond R, Lincoff AM (2013) Management of the patient with diabetes and coronary artery disease: a contemporary review. Future Cardiol 9: 387-403.
4. Cleland SJ (2012) Cardiovascular risk in double diabetes mellitus - when two worlds collide. Nat Rev Endocrinol 8: 476-485.
5. Brom CE, Bosmans JW, Vlasblom R, Handoko LM, Huisman MC, et al. (2010) Diabetic cardiomyopathy in Zucker diabetic fatty rats: the forgotten right ventricle. Cardiovasc Diabetol 9: 25.
6. Olsen KB, Axelsen LN, Braunstein TH, Sørensen CM, Andersen CB, et al. (2013) Myocardial impulse propagation is impaired in right ventricular tissue of Zucker diabetic fatty (ZDF) rats. Cardiovasc Diabetol 12: 19.
7. Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M (2012) The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics 44: 237-244.
8. Nielsen LB, Wang C, Sørensen K, Bang-Berthelsen CH, Hansen L, et al. (2012) Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res 896:362
9. Long J, Wang Y, Wang W, Chang BH, Danesh FR (2011) MicroRNA-29c is a signature microRNA under high glucose conditions that targets Sprouty homolog 1, and its in vivo knockdown prevents progression of diabetic nephropathy. J Biol Chem 286: 11837-11848.
10. Maegdefessel L, Azuma J, Tsao PS (2014) MicroRNA-29b regulation of abdominal aortic aneurysm development. Trends Cardiovasc Med 24: 1-6.
11. He A, Zhu L, Gupta N, Chang Y, Fang F (2007) Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 21: 2785-2794. (Pubitemid 350035159)
12. Pandey AK, Verma G, Vig S, Srivastava S, Srivastava AK, et al. (2011) miR-29a levels are elevated in the db/db mice liver and its overexpression leads to attenuation of insulin action on PEPCK gene expression in HepG2 cells. Mol Cell Endocrinol 332: 125-133.
13. Ye Y, Hu Z, Lin Y, Zhang C, Perez-Polo JR (2010) Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc Res 87: 535-544.
14. Hulsmans M, Holvoet P (2013) MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. Cardiovasc Res 100: 7-18.
15. Roggli E, Gattesco S, Caille D, Briet C, Boitard C, et al. (2012) Changes in microRNA expression contribute to pancreatic β-cell dysfunction in prediabetic NOD mice. Diabetes 61: 1742-1745.
16. Wang X, Bathina M, Lynch J, Koss B, Calabrese C, et al. (2013) Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev 27: 1351-1364.
17. Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, et al. (2013) Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev 27: 1365-1377.
18. Barlow AD, Nicholson ML, Herbert TP (2013) Evidence for Rapamycin Toxicity in Pancreatic β-Cells and a Review of the Underlying Molecular Mechanisms. Diabetes 62: 2674-2678.
19. Sofroniadou S, Goldsmith D (2011) Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects. Drug Saf 34: 97-115.
20. Johnston O, Rose CL, Webster AC, Gill JS (2008) Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 19: 1411-1418.
21. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, et al. (2008) mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57: 945-957.
22. Houde VP, BrÛlé S, Festuccia WT, Blanchard PG, Bellmann K, et al. (2010) Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59: 1338-1348.
23. Chang GR, Wu YY, Chiu YS, Chen WY, Liao JW, et al. (2009) Long-term administration of rapamycin reduces adiposity, but impairs glucose tolerance in high-fat diet-fed KK/HlJ mice. Basic Clin Pharmacol Toxicol 105: 188-198.
24. Deblon N, Bourgoin L, Veyrat-Durebex C, Peyrou M, Vinciguerra M, et al. (2012) Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br J Pharmacol 165: 2325-2340.
25. White SM, Constantin PE, Claycomb WC (2004) Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am J Physiol Heart Circ Physiol 286: H823-H829. (Pubitemid 38248592)
26. Clark JB, Palmer CJ, Shaw WN (1983) The diabetic Zucker fatty rat. Proc Soc Exp Biol Med 173: 68-75. (Pubitemid 13088195)
27. Pulakat L, Demarco VG, Ardhanari S, Chockalingam A, Gul R, et al. (2011) Adaptive Mechanisms to Compensate for Overnutrition-induced Cardiovascular Abnormalities. Am J Physiol Regul Integr Comp Physiol 301: R885-R895.
28. Erickson CE, Gul R, Blessing CP, Nguyen J, Liu T, et al. (2013) The β-blocker Nebivolol Is a GRK/β-arrestin Biased Agonist. PLoS ONE 8(8): e71980. doi:10.1371/journal.pone.0071980
29. Kovner I, Taicher GZ, Mitchell AD (2010) Calibration and validation of EchoMRI whole body composition analysis based on chemical analysis of piglets, in comparison with the same for DXA. Int J Body Compos Res 8: 17-
30. Pulakat L, Cooper S, Knowle D, Mandavia C, Bruhl S, et al. (2005) Ligand-dependent complex formation between the Angiotensin II receptor subtype AT2 and Na+/H+ exchanger NHE6 in mammalian cells. Peptides 26: 863-873. (Pubitemid 40461668)
31. Lombardi R, Rodriguez G, Chen SN, Ripplinger CM, Li W, et al. (2009) Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation. 119:1398-1407
32. Sengupta S, Peterson TR, Sabatini DM (2010) Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 40: 310-322.
33. Cencic R, Hall DR, Robert F, Du Y, Min J, et al. (2011) Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci U S A 108: 1046-1051.
34. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35.
35. Rajan MR, Fagerholm S, Jönsson C, Kjølhede P, Turkina MV, et al. (2013) Phosphorylation of IRS1 at Serine 307 in Response to Insulin in Human Adipocytes Is Not Likely to be Catalyzed by p70 Ribosomal S6 Kinase. PLoS ONE 8(4): e59725.
36. Cencic R, Hall DR, Robert F, Du Y, Min J, et al. (2011) Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F. Proc Natl Acad Sci U S A. 108:1046-1051.
37. Shioi T, McMullen JR, Tarnavski O, Converso K, Sherwood MC, et al. (2003) Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107: 1664-1670. (Pubitemid 36397337)
38. Faden G, Faganello G, De Feo S, Berlinghieri N, Tarantini L, et al. (2013) The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study. Diabetes Res Clin Pract 101: 309-316.
39. Bergner DW, Goldberger JJ (2010) Diabetes mellitus and sudden cardiac death: what are the data? Cardiol J 17: 117-129.
40. Zoja C, Cattaneo S, Fiordaliso F, Lionetti V, Zambelli V, et al. (2011) Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. Am J Physiol Renal Physiol 301: F1114-F1123.
41. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, et al. (2010) Inhibition of mTOR by Rapamycin Abolishes Cognitive Deficits and Reduces Amyloid-β Levels in a Mouse Model of Alzheimer's Disease. PLoS ONE 5(4): e9979.
42. Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, et al. (2003) Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 63: 917-926. (Pubitemid 36315569)
43. Rizell M, Lindner P (2005) Inhibition of mTOR suppresses experimental liver tumours. Anticancer Res 25: 789-793. (Pubitemid 40546845)
44. Das A, Durrant D, Koka S, Salloum FN, Xi L, et al. (2014) Mammalian target of rapamycin (mTOR) inhibition with Rapamycin Improves Cardiac Function in Type 2 Diabetic Mice: Potential Role of Attenuated Oxidative Stress and Altered Contractile Protein Expression. J Biol Chem. 289: 4145-60.
45. Peng H, Zhong M, Zhao W, Wang C, Zhang J, et al. (2013) Urinary miR-29 correlates with albuminuria and carotid intima-media thickness in type 2 diabetes patients. PLoS One 8(12):e82607.